Was cash involved in the CFO’s BioNexus Gene Lab Corp (BGLC) share award?

No cash was involved. The filing states the 96,774-share award was granted for completed services, for no cash consideration , under the 2025 Equity Incentive Plan, reflecting non-cash equity compensation rather than an open-market purchase.

BioNexus Gene Lab Corp (BGLC) CFO receives 96,774-share equity award

Q: What transaction did BioNexus Gene Lab Corp (BGLC) report for its CFO?

BioNexus Gene Lab Corp reported that its CFO, Chong Set Fui , received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The grant was made for completed services under the 2025 Equity Incentive Plan .

Q: How many BGLC shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Chong Set Fui directly holds 96,774 common shares of BioNexus Gene Lab Corp. All of these shares come from the fully vested Other Stock-Based Award granted on August 13, 2026.

Q: At what price was the BGLC CFO’s stock award valued for plan purposes?

The 96,774 BioNexus Gene Lab Corp shares awarded to the CFO were valued for plan purposes at $1.55 per share , which the company identifies as the Nasdaq closing price for its common stock on August 12, 2026.

Q: What type of equity award did the BioNexus Gene Lab Corp (BGLC) CFO receive?

CFO Chong Set Fui received a fully vested Other Stock-Based Award consisting of 96,774 common shares, no par value. The award was granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan for completed services.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Chong Set Fui reported acquisition or exercise transactions in this Form 4 filing.

BioNexus Gene Lab Corp’s Chief Financial Officer, Chong Set Fui, received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, with no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, Chong Set Fui directly holds 96,774 common shares.

Insider Trade Summary

Net Buyer: 96,774 shares

Net Buy 1 txn

Insider Chong Set Fui

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares ^F1	96,774	--	--

Holdings After Transaction: Common Shares — 96,774 shares (Direct)

Footnotes (1)

F1. Represents a fully vested Other Stock-Based Award of 96,774 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

Key Figures

Shares awarded: 96,774 common shares Per-share award value: $1.55 per share Shares held after transaction: 96,774 common shares +1 more

4 metrics

Shares awarded 96,774 common shares Fully vested Other Stock-Based Award granted to CFO on August 13, 2026

Per-share award value $1.55 per share Valued for plan purposes at Nasdaq closing price on August 12, 2026

Shares held after transaction 96,774 common shares Direct holdings of CFO Chong Set Fui following the award

Equity plan year 2025 Award granted under the BioNexus Gene Lab Corp 2025 Equity Incentive Plan

Key Terms

Other Stock-Based Award, Equity Incentive Plan, no cash consideration, Nasdaq closing price

4 terms

Other Stock-Based Award financial

"Represents a fully vested Other Stock-Based Award of 96,774 shares of common stock"

Equity Incentive Plan financial

"granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

no cash consideration financial

"The award was granted for completed services, for no cash consideration"

Nasdaq closing price market

"valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026)"

FAQ

What transaction did BioNexus Gene Lab Corp (BGLC) report for its CFO?

BioNexus Gene Lab Corp reported that its CFO, Chong Set Fui, received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The grant was made for completed services under the 2025 Equity Incentive Plan.

How many BGLC shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Chong Set Fui directly holds 96,774 common shares of BioNexus Gene Lab Corp. All of these shares come from the fully vested Other Stock-Based Award granted on August 13, 2026.

At what price was the BGLC CFO’s stock award valued for plan purposes?

The 96,774 BioNexus Gene Lab Corp shares awarded to the CFO were valued for plan purposes at $1.55 per share, which the company identifies as the Nasdaq closing price for its common stock on August 12, 2026.

What type of equity award did the BioNexus Gene Lab Corp (BGLC) CFO receive?

CFO Chong Set Fui received a fully vested Other Stock-Based Award consisting of 96,774 common shares, no par value. The award was granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan for completed services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:18 PM Accepted by SEC EDGAR 08/14/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chong Set Fui

(Last)

(First)

(Middle)

UNIT:A-28-7, TOWER A

MENARA UOA BANGSAR, NO.5

(Street)

KUALA LUMPUR

59000

(City)

(State)

(Zip)

MALAYSIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNexus Gene Lab Corp [ BGLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	08/13/2026		A		96,774	A	⁽¹⁾	96,774	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a fully vested Other Stock-Based Award of 96,774 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

	/s/ Set Fui Chong	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR